Literature DB >> 2205418

Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Evidence for a protective effect of thrombolytic therapy. GISSI Investigators.

A Volpi1, A Cavalli, E Santoro, G Tognoni.   

Abstract

The multicenter randomized study of the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico has provided the opportunity to analyze the impact of thrombolytic treatment on secondary ventricular fibrillation incidence in a large population of patients (11,712) with acute myocardial infarction. A reduction of about 20% in the frequency of secondary ventricular fibrillation was observed among patients allocated to thrombolytic treatment (streptokinase, 2.4% versus control, 2.9%; relative risk, 0.80; 95% confidence interval, 0.64-1.00). Streptokinase appeared to exert its protective effect specifically in patients treated within 3 hours of onset of symptoms (streptokinase, 2.6% versus control, 3.7%; relative risk, 0.71; 95% confidence interval, 0.53-0.95). This protection was essentially due to a reduced incidence of late ventricular fibrillation occurring after the first day of hospitalization. The 311 patients with secondary ventricular fibrillation represented an overall incidence of 2.7%. Such incidence was not related to infarct location or sex but was significantly more common in patients older than 65 years (3.3% versus 2.3% in younger patients). A significant excess of in-hospital deaths was found in patients with secondary ventricular fibrillation compared with those in the reference group (38% versus 24%; relative risk, 1.98; 95% confidence interval, 1.56-2.52). Conversely, secondary ventricular fibrillation was not a predictor of 1-year mortality for hospital survivors. Thrombolytic treatment with intravenous streptokinase affords protection against secondary ventricular fibrillation most probably by a limitation of infarct size. When the arrhythmia complicates the course of infarction, it is associated with an adverse short-term outcome, whereas the long-term prognosis is not influenced.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205418     DOI: 10.1161/01.cir.82.4.1279

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

1.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  The open-artery hypothesis revisited.

Authors:  Alireza Zarrabi; Hossein Eftekhari; S Ward Casscells; Mohammad Madjid
Journal:  Tex Heart Inst J       Date:  2006

3.  Timing, setting and incidence of cardiovascular complications in patients with acute myocardial infarction submitted to primary percutaneous coronary intervention.

Authors:  Cristina Giglioli; Massimo Margheri; Serafina Valente; Marco Comeglio; Chiara Lazzeri; Tania Chechi; Corinna Armentano; Salvatore Mario Romano; Massimilano Falai; Gian Franco Gensini
Journal:  Can J Cardiol       Date:  2006-10       Impact factor: 5.223

Review 4.  Prophylactic lidocaine for myocardial infarction.

Authors:  Arturo J Martí-Carvajal; Daniel Simancas-Racines; Vidhu Anand; Shrikant Bangdiwala
Journal:  Cochrane Database Syst Rev       Date:  2015-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.